Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Cancer Lett. 2011 Dec 11;318(1):99–105. doi: 10.1016/j.canlet.2011.12.007

Fig. 6.

Fig. 6

Combination of anti-TRPM7 siRNA with gemcitabine produced enhanced cytotoxicity. PANC-1 cells transfected with anti-TRPM7 siRNA or non-targeting control siRNA were incubated in the presence or absence of gemcitabine at 1 µM or 5 µM and then analyzed for proliferation using the MTS assay. Each column represents the mean (+ s.d.) proliferation as indicated by MTS absorbance relative to that of control (cells transfected with non-targeting control siRNA and incubated in the absence of gemcitabine). Statistical analysis was performed by comparing each experimental group with control except where indicated. *P < 0.01 and #P < 0.001 indicates statistically significant difference; @P < 0.1, a statistical trend; NS, not statistically significant. This experiment was repeated twice with similar results.